Cargando…

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial

To evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks. METHODS: We conducted a phase 3, randomized, double-blind, 52-week safety study (SKYLIGHT 4 [Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Throu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neal-Perry, Genevieve, Cano, Antonio, Lederman, Samuel, Nappi, Rossella E., Santoro, Nanette, Wolfman, Wendy, English, Marci, Franklin, Catherine, Valluri, Udaya, Ottery, Faith D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Gynecology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026946/ https://www.ncbi.nlm.nih.gov/pubmed/36897180 http://dx.doi.org/10.1097/AOG.0000000000005114

Ejemplares similares

OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
por: Johnson, Kimball A, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
por: Fraser, Graeme L., et al.
Publicado: (2020)

“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
por: Santoro, Nanette, et al.
Publicado: (2020)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms
por: Langley, Paul C
Publicado: (2023)

Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
por: Cintron, Dahima, et al.
Publicado: (2018)

Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden
por: Nappi, Rossella E., et al.
Publicado: (2021)

Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls
por: Forslund, Maria, et al.
Publicado: (2018)

Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action
por: Abdi, Fatemeh, et al.
Publicado: (2016)

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep
por: English, Marci, et al.
Publicado: (2021)

Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep
por: English, Marci, et al.
Publicado: (2021)

Association of Menopausal Vasomotor Symptoms With Increased Bone Turnover During the Menopausal Transition
por: Crandall, Carolyn J, et al.
Publicado: (2011)

Prevalence of Metabolic Syndrome and Its Association With Menopausal Symptoms in Post-Menopausal Women: A Scoping Review
por: Raman, Vishal, et al.
Publicado: (2023)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms
por: Singhal, Savita Rani, et al.
Publicado: (2016)

Vasomotor and physical menopausal symptoms are associated with sleep quality
por: Kim, Min-Ju, et al.
Publicado: (2018)

Psychosomatic and vasomotor symptom changes during transition to menopause
por: Augoulea, Areti, et al.
Publicado: (2019)

MON-387 Pheochromocytoma Masquerading as Vasomotor Menopausal Symptoms
por: Xhikola, Majlinda, et al.
Publicado: (2019)

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms
por: Ryu, Ki-Jin, et al.
Publicado: (2020)

Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms
por: Yang, Yihui, et al.
Publicado: (2023)

Determinants of Menopausal Symptoms and Attitude Towards Menopause Among Midlife Women: A Cross-Sectional Study in South India
por: Durairaj, Anitha, et al.
Publicado: (2022)

A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial
por: Barnard, Neal D., et al.
Publicado: (2023)

The Genitourinary Syndrome of Menopause: An Overview of the Recent Data
por: Angelou, Kyveli, et al.
Publicado: (2020)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

Uterine Lipoleiomyoma Presenting With Pelvic Pain in a Post-Menopausal Woman
por: Rampersad, Fidel S, et al.
Publicado: (2021)

Metastatic Leiomyoma Following Menopause: A Case Report and Review of Literature
por: Otsuka, Shoko, et al.
Publicado: (2022)

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review
por: Utian, Wulf H
Publicado: (2005)

Investigation of the relationship between personality characteristics and vasomotor symptoms in menopausal women
por: Ghorbani, Mahboubeh, et al.
Publicado: (2016)

RANKL is a new Epigenetic Biomarker for the Vasomotor Symptom During Menopause
por: Kalkan, R, et al.
Publicado: (2020)

Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN
por: Thurston, Rebecca C., et al.
Publicado: (2021)

Frequency of Thyroid Disorder in Pre- and Postmenopausal Women and Its Association With Menopausal Symptoms
por: Yadav, Manjusha, et al.
Publicado: (2023)

Do Menopause and Aging Affect the Onset and Progression of Rheumatoid Arthritis and Systemic Lupus Erythematosus?
por: Shah, Lisa, et al.
Publicado: (2020)

Efficacy of Two Laser Treatment Strategies for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
por: Okui, Nobuo, et al.
Publicado: (2023)

Impact of Lumbar Postures on the Functioning of Pelvic Floor Muscles Among Osteoporotic Post-Menopausal Women
por: Chhibber, Bhumika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3vec7uk3s8s22t7peqe3g70gca